Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Diabetes | Research

Differential evolution of diabetic ketoacidosis in adults with pre-existent versus newly diagnosed type 1 and type 2 diabetes mellitus

Authors: Fateen Ata, Adeel Ahmad Khan, Ibrahim Khamees, Baian Z. M. Mohammed, Haidar Hussein Barjas, Bassam Muthanna, Mohammed Bashir, Anand Kartha

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Diabetic ketoacidosis (DKA) was once known to be specific to type-1 diabetes-mellitus (T1D); however, many cases are now seen in patients with type-2 diabetes-mellitus (T2D). Little is known about how this etiology shift affects DKA's outcomes.

Methods

We studied consecutive index DKA admissions from January 2015 to March 2021. Descriptive analyses were performed based on pre-existing T1D and T2D (PT1D and PT2D, respectively) and newly diagnosed T1D and T2D (NT1D and NT2D, respectively).

Results

Of the 922 patients, 480 (52%) had T1D, of which 69% had PT1D and 31% NT1D, whereas 442 (48%) had T2D, of which 60% had PT2D and 40% NT2D. The mean age was highest in PT2D (47.6 ± 13.1 years) and lowest in PT1D (27.3 ± 0.5 years) (P < 0.001). Patients in all groups were predominantly male except in the PT1D group (55% females) (P < 0.001). Most patients were Arabic (76% in PT1D, 51.4% in NT1D, 46.6% in PT2D) except for NT2D, which mainly comprised Asians (53%) (P < 0.001). Patients with NT2D had the longest hospital length of stay (LOS) (6.8 ± 11.3 days) (P < 0.001), longest DKA duration (26.6 ± 21.1 h) (P < 0.001), and more intensive-care unit (ICU) admissions (31.2%) (P < 0.001). Patients with PT1D had the shortest LOS (2.5 ± 3.5 days) (P < 0.001), DKA duration (18.9 ± 4.2 h) (P < 0.001), and lowest ICU admissions (16.6%) (P < 0.001).

Conclusions/interpretation

We presented the largest regional data on differences in DKA based on the type and duration of diabetes- mellitus (DM), showing that T2D is becoming an increasing cause of DKA, with worse clinical outcomes (especially newly diagnosed T2D) compared to T1D.
Literature
1.
go back to reference Xu AC, Broome DT, Bena JF, Lansang MC. Predictors for adverse outcomes in diabetic ketoacidosis in a multihospital health system. Endocr Pract. 2020;26(3):259–66.CrossRefPubMed Xu AC, Broome DT, Bena JF, Lansang MC. Predictors for adverse outcomes in diabetic ketoacidosis in a multihospital health system. Endocr Pract. 2020;26(3):259–66.CrossRefPubMed
2.
go back to reference Gouin PE, Gossain VV, Rovner DR. Diabetic ketoacidosis: outcome in a community hospital. South Med J. 1985;78(8):941–3.CrossRefPubMed Gouin PE, Gossain VV, Rovner DR. Diabetic ketoacidosis: outcome in a community hospital. South Med J. 1985;78(8):941–3.CrossRefPubMed
3.
go back to reference Fazeli Farsani S, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open. 2017;7(7):e016587.CrossRefPubMed Fazeli Farsani S, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open. 2017;7(7):e016587.CrossRefPubMed
4.
go back to reference Puttanna A, Padinjakara R. Diabetic ketoacidosis in type 2 diabetes mellitus. Practical Diabetes. 2014;31(4):155–8.CrossRef Puttanna A, Padinjakara R. Diabetic ketoacidosis in type 2 diabetes mellitus. Practical Diabetes. 2014;31(4):155–8.CrossRef
5.
go back to reference Welch BJ, Zib I. Case study: diabetic ketoacidosis in type 2 diabetes: “Look Under the Sheets.” Clin Diabetes. 2004;22(4):198–200.CrossRef Welch BJ, Zib I. Case study: diabetic ketoacidosis in type 2 diabetes: “Look Under the Sheets.” Clin Diabetes. 2004;22(4):198–200.CrossRef
6.
go back to reference Thibault V, Bélanger M, LeBlanc E, Babin L, Halpine S, Greene B, Mancuso M. Factors that could explain the increasing prevalence of type 2 diabetes among adults in a Canadian province: a critical review and analysis. Diabetol Metab Syndr. 2016;8(1):71.CrossRefPubMedPubMedCentral Thibault V, Bélanger M, LeBlanc E, Babin L, Halpine S, Greene B, Mancuso M. Factors that could explain the increasing prevalence of type 2 diabetes among adults in a Canadian province: a critical review and analysis. Diabetol Metab Syndr. 2016;8(1):71.CrossRefPubMedPubMedCentral
7.
go back to reference Passanisi S, Salzano G, Aloe M, Bombaci B, Citriniti F, De Berardinis F, De Marco R, Lazzaro N, Lia MC, Lia R, et al. Increasing trend of type 1 diabetes incidence in the pediatric population of the Calabria region in 2019–2021. Ital J Pediatr. 2022;48(1):66.CrossRefPubMedPubMedCentral Passanisi S, Salzano G, Aloe M, Bombaci B, Citriniti F, De Berardinis F, De Marco R, Lazzaro N, Lia MC, Lia R, et al. Increasing trend of type 1 diabetes incidence in the pediatric population of the Calabria region in 2019–2021. Ital J Pediatr. 2022;48(1):66.CrossRefPubMedPubMedCentral
8.
go back to reference Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–11.CrossRefPubMedPubMedCentral Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–11.CrossRefPubMedPubMedCentral
9.
go back to reference Song SH. Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population. BMJ Open Diabetes Res Care. 2015;3(1):e000044.CrossRefPubMedPubMedCentral Song SH. Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population. BMJ Open Diabetes Res Care. 2015;3(1):e000044.CrossRefPubMedPubMedCentral
10.
go back to reference Kim MK, Lee SH, Kim JH, Lee JI, Kim JH, Jang EH, Yoon KH, Lee KW, Song KH. Clinical characteristics of Korean patients with new-onset diabetes presenting with diabetic ketoacidosis. Diabetes Res Clin Pract. 2009;85(1):e8-11.CrossRefPubMed Kim MK, Lee SH, Kim JH, Lee JI, Kim JH, Jang EH, Yoon KH, Lee KW, Song KH. Clinical characteristics of Korean patients with new-onset diabetes presenting with diabetic ketoacidosis. Diabetes Res Clin Pract. 2009;85(1):e8-11.CrossRefPubMed
11.
go back to reference Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia. 2004;47(3):581–9.CrossRefPubMed Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia. 2004;47(3):581–9.CrossRefPubMed
12.
go back to reference Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med. 2004;164(17):1925–31.CrossRefPubMed Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med. 2004;164(17):1925–31.CrossRefPubMed
13.
go back to reference Zhong VW, Juhaeri J, Mayer-Davis EJ. Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care. 2018;41(9):1870–7.CrossRefPubMed Zhong VW, Juhaeri J, Mayer-Davis EJ. Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care. 2018;41(9):1870–7.CrossRefPubMed
14.
go back to reference Charoenpiriya A, Chailurkit L, Ongphiphadhanakul B. Comparisons of biochemical parameters and diabetic ketoacidosis severity in adult patients with type 1 and type 2 diabetes. BMC Endocr Disord. 2022;22(1):7.CrossRefPubMedPubMedCentral Charoenpiriya A, Chailurkit L, Ongphiphadhanakul B. Comparisons of biochemical parameters and diabetic ketoacidosis severity in adult patients with type 1 and type 2 diabetes. BMC Endocr Disord. 2022;22(1):7.CrossRefPubMedPubMedCentral
16.
go back to reference Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019;63:9–14.CrossRefPubMed Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019;63:9–14.CrossRefPubMed
17.
go back to reference Ooi E, Nash K, Rengarajan L, Melson E, Thomas L, Johnson A, Zhou D, Wallett L, Ghosh S, Narendran P, et al. Clinical and biochemical profile of 786 sequential episodes of diabetic ketoacidosis in adults with type 1 and type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2021;9(2):e002451.CrossRef Ooi E, Nash K, Rengarajan L, Melson E, Thomas L, Johnson A, Zhou D, Wallett L, Ghosh S, Narendran P, et al. Clinical and biochemical profile of 786 sequential episodes of diabetic ketoacidosis in adults with type 1 and type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2021;9(2):e002451.CrossRef
18.
go back to reference Ebrahimi F, Kutz A, Christ ER, Szinnai G. Lifetime risk and health-care burden of diabetic ketoacidosis: a population-based study. Front Endocrinol (Lausanne). 2022;13:940990.CrossRefPubMed Ebrahimi F, Kutz A, Christ ER, Szinnai G. Lifetime risk and health-care burden of diabetic ketoacidosis: a population-based study. Front Endocrinol (Lausanne). 2022;13:940990.CrossRefPubMed
19.
go back to reference Lyerla R, Johnson-Rabbett B, Shakally A, Magar R, Alameddine H, Fish L. Recurrent DKA results in high societal costs - a retrospective study identifying social predictors of recurrence for potential future intervention. Clin Diabetes Endocrinol. 2021;7(1):13.CrossRefPubMedPubMedCentral Lyerla R, Johnson-Rabbett B, Shakally A, Magar R, Alameddine H, Fish L. Recurrent DKA results in high societal costs - a retrospective study identifying social predictors of recurrence for potential future intervention. Clin Diabetes Endocrinol. 2021;7(1):13.CrossRefPubMedPubMedCentral
20.
go back to reference Gopalan A, Mishra P, Alexeeff SE, Blatchins MA, Kim E, Man AH, Grant RW. Prevalence and predictors of delayed clinical diagnosis of Type 2 diabetes: a longitudinal cohort study. Diabet Med. 2018;35(12):1655–62.CrossRefPubMedPubMedCentral Gopalan A, Mishra P, Alexeeff SE, Blatchins MA, Kim E, Man AH, Grant RW. Prevalence and predictors of delayed clinical diagnosis of Type 2 diabetes: a longitudinal cohort study. Diabet Med. 2018;35(12):1655–62.CrossRefPubMedPubMedCentral
21.
go back to reference Zhu M, Liu X, Liu W, Lu Y, Cheng J, Chen Y. β cell aging and age-related diabetes. Aging (Albany NY). 2021;13(5):7691–706.CrossRefPubMed Zhu M, Liu X, Liu W, Lu Y, Cheng J, Chen Y. β cell aging and age-related diabetes. Aging (Albany NY). 2021;13(5):7691–706.CrossRefPubMed
22.
go back to reference Prasad RB, Asplund O, Shukla SR, Wagh R, Kunte P, Bhat D, Parekh M, Shah M, Phatak S, Käräjämäki A, et al. Subgroups of patients with young-onset type 2 diabetes in India reveal insulin deficiency as a major driver. Diabetologia. 2022;65(1):65–78.CrossRefPubMed Prasad RB, Asplund O, Shukla SR, Wagh R, Kunte P, Bhat D, Parekh M, Shah M, Phatak S, Käräjämäki A, et al. Subgroups of patients with young-onset type 2 diabetes in India reveal insulin deficiency as a major driver. Diabetologia. 2022;65(1):65–78.CrossRefPubMed
23.
go back to reference Fragala MS, Shiffman D, Birse CE. Population health screenings for the prevention of chronic disease progression. Am J Manag Care. 2019;25(11):548–53.PubMed Fragala MS, Shiffman D, Birse CE. Population health screenings for the prevention of chronic disease progression. Am J Manag Care. 2019;25(11):548–53.PubMed
24.
go back to reference Mamo Y, Bekele F, Nigussie T, Zewudie A. Determinants of poor glycemic control among adult patients with type 2 diabetes mellitus in Jimma University Medical Center, Jimma zone, south west Ethiopia: a case control study. BMC Endocr Disord. 2019;19(1):91.CrossRefPubMedPubMedCentral Mamo Y, Bekele F, Nigussie T, Zewudie A. Determinants of poor glycemic control among adult patients with type 2 diabetes mellitus in Jimma University Medical Center, Jimma zone, south west Ethiopia: a case control study. BMC Endocr Disord. 2019;19(1):91.CrossRefPubMedPubMedCentral
25.
go back to reference Hwang J, Shon C. Relationship between socioeconomic status and type 2 diabetes: results from Korea National Health and Nutrition Examination Survey (KNHANES) 2010–2012. BMJ Open. 2014;4(8):e005710.CrossRefPubMedPubMedCentral Hwang J, Shon C. Relationship between socioeconomic status and type 2 diabetes: results from Korea National Health and Nutrition Examination Survey (KNHANES) 2010–2012. BMJ Open. 2014;4(8):e005710.CrossRefPubMedPubMedCentral
26.
go back to reference Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol. 2009;15(33):4137–42.CrossRefPubMedPubMedCentral Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol. 2009;15(33):4137–42.CrossRefPubMedPubMedCentral
Metadata
Title
Differential evolution of diabetic ketoacidosis in adults with pre-existent versus newly diagnosed type 1 and type 2 diabetes mellitus
Authors
Fateen Ata
Adeel Ahmad Khan
Ibrahim Khamees
Baian Z. M. Mohammed
Haidar Hussein Barjas
Bassam Muthanna
Mohammed Bashir
Anand Kartha
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01446-8

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine